Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) 2024-02
Main Authors: Jaramillo, Sonia, Krisam, Johannes, Le Cornet, Lucian, Kratzmann, Markus, Baumann, Lukas, Eissymont, Olga, Crysandt, Martina, Görner, Martin, Kayser, Sabine, Krause, Stefan, Schliemann, Christoph, Gaska, Tobias, Kaufmann, Martin, Chemnitz, Jens, Schaich, Markus, Hoellein, Alexander, Platzbecker, Uwe, Kieser, Meinhard, Müller-Tidow, Carsten, Schlenk, Richard F.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0390-6078
1592-8721
DOI:10.3324/haematol.2023.284346